1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Drugs In Development, 2022, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 12, 51, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 15 and 16 molecules, respectively.
Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Zika Virus Infections - Overview
- Zika Virus Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Zika Virus Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Zika Virus Infections - Companies Involved in Therapeutics Development
- Zika Virus Infections - Drug Profiles
- Zika Virus Infections - Dormant Projects
- Zika Virus Infections - Discontinued Products
- Zika Virus Infections - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Zika Virus Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Zika Virus Infections - Dormant Projects, 2022
- Zika Virus Infections - Dormant Projects, 2022 (Contd..2)
- Zika Virus Infections - Discontinued Products, 2022
- Number of Products under Development for Zika Virus Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acer Therapeutics Inc
- Activirosomes Ltd
- Acuitas Therapeutics Inc
- Altimmune Inc
- Ascendo Biotechnology Inc
- Autonomous Therapeutics Inc
- Bharat Biotech Ltd
- BioCryst Pharmaceuticals Inc
- BioNet-Asia Co Ltd
- Biotron Ltd
- BravoVax Co Ltd
- Bugworks Research Inc
- CanSino Biologics Inc
- Cidara Therapeutics Inc
- Ciloa
- Cocrystal Pharma Inc
- Codagenix Inc
- Emergent BioSolutions Inc
- Emergex Vaccines Holding Ltd
- Enesi Pharma Ltd
- Ennaid Therapeutics LLC
- Enyo Pharma SA
- Eurocine Vaccines AB
- Excivion Ltd
- Expres2ion Biotechnologies ApS
- GeneOne Life Science Inc
- GeoVax Labs Inc
- GigaGen Inc
- Greffex Inc
- Hawaii Biotech Inc
- Hercules Pharmaceuticals BV
- IDBiologics Inc
- ImmunityBio Inc
- Imutex Ltd
- IMV Inc
- Indian Immunologicals Ltd
- Inovio Pharmaceuticals Inc
- iosBio Pharma Ltd
- Island Pharmaceuticals Ltd
- Johnson & Johnson
- Kamada Pharmaceuticals
- KM Biologics Co Ltd
- L2 Diagnostics LLC
- Mabloc LLC
- Macrophage Therapeutics Inc
- Medigen Inc
- Meletios Therapeutics SAS
- Merck & Co Inc
- Microbiotix Inc
- Moderna Inc
- Moleculin Biotech Inc
- NanoViricides Inc
- NightHawk Biosciences Inc
- Novalex Therapeutics Inc
- Ostrich Pharma USA Inc
- Palisades Therapeutics
- Plex Pharmaceuticals Inc
- Precision Virologics Inc
- ProtInhi BV
- Replikins Ltd
- ReVacc Biotech
- Riboscience LLC
- Sanofi
- Sementis Ltd
- Shanghai Junshi Bioscience Co Ltd
- Takeda Pharmaceutical Co Ltd
- TechnoVax Inc
- TenGen Biomedical Co
- Theravectys SA
- Tiba Biotech LLC
- Touchlight Genetics Ltd
- TrippBio Inc
- Tychan Pte Ltd
- Uvax Bio LLC
- VBI Vaccines Inc
- VenatoRx Pharmaceuticals Inc
- Vir Biotechnology Inc
- Virocovax
- Xenothera SAS
